Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Cancer: early-phase trial registry
101 of 283 indexed Pancreatic Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 101 currently recruiting · #33 of 28,707 conditions by registered trial count
Pancreatic Cancer: 283 US clinical trials tracked, 101 recruiting.
Pancreatic Cancer is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 101 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 180 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition pancreatic-cancer
OPEN 101 | RECR 36% | LATE 12 | EARLY 180 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
Pancreatic Cancer lists 101 open slots (36% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Cancer recruits in line with its size-band peers.
101 of 283 indexed trials (35.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 19 of 283 trials (6.7%). 165 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 279 trials that report a genuine target (sentinel values excluded). 170 of those (60.9%) plan for fewer than 100 participants.
-
Pancreatic Cancer research is mostly interventional.
237 interventional and 46 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 1 of 6
Integrated Cancer Repository for Cancer Research
University of Nebraska
NCT02012699
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Mayo Clinic
NCT00830557
Pancreatic Adenocarcinoma Gene Environment Risk Study
University of Pittsburgh
NCT00912717
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
NCT06122896
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Mayo Clinic
NCT06151223
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Vanderbilt University Medical Center
NCT00899626
UCSF PANC Cyst Registry
University of California, San Francisco
NCT04291651
Pancreatic Cancer Detection Consortium
City of Hope Medical Center
NCT06388967
EXoPERT EMERALD Clinical Study
EXoPERT
NCT07186296
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
H. Lee Moffitt Cancer Center and Research Institute
NCT04275557
Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NCT05225428
PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease
Columbia University
NCT01102556
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
Nuvance Health
NCT03937453
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
M.D. Anderson Cancer Center
NCT03460769
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT03334708
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
University of Missouri-Columbia
NCT02838836
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Global Development
NCT07409272
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines
NCT07349537
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
AbbVie
NCT05005403
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines
NCT07252232
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
University of Louisville
NCT02674100
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT04751435
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ArriVent BioPharma
NCT07066657
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Frontier Medicines Corporation
NCT06244771
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
University of Missouri-Columbia
NCT03551951
Artificial Intelligence in Endoscopic Ultrasound
Orlando Health
NCT06564571
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
M.D. Anderson Cancer Center
NCT02361320
Resilience and Equity in Aging, Cancer, and Health (REACH)
Dana-Farber Cancer Institute
NCT04674267
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono Research & Development Institute
NCT06710132
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03935893
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics
NCT04421820
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
Abramson Cancer Center at Penn Medicine
NCT02478892
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PAQ Therapeutics
NCT07300150
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT02393703
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Reema A. Patel
NCT05391126
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
NCT07127874
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen
NCT05989724
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
Orlando Health
NCT06340620
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics
NCT04678648
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
Varian, a Siemens Healthineers Company
NCT05764720
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
Medical College of Wisconsin
NCT03322995
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
H. Lee Moffitt Cancer Center and Research Institute
NCT05687188
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
NCT02830724
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AtlasMedx, Incorporated
NCT04503265
A First-in-Human Study of FID-022 in Solid Tumor Patients
H. Lee Moffitt Cancer Center and Research Institute
NCT07249775
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 114 |
| Phase 2 | 66 |
| Phase 3 | 10 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Cancer page
283 registered trials, 101 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 101 Pancreatic Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Pancreatic Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer condition card totals 283 registered trials; most-linked intervention Gemcitabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.